US intellectual property (IP) rules and a string of recent court cases are reducing the types of inventions pharma companies can patent, and “calling into question entire portfolios,” says a specialist lawyer. …
Sourced through Scoop.it from: www.in-pharmatechnologist.com


Leave a comment